中国神经再生研究(英文版) ›› 2024, Vol. 19 ›› Issue (11): 2341-2342.doi: 10.4103/NRR.NRR-D-23-01784

• 观点:脑损伤修复保护与再生 • 上一篇    下一篇

外周血单核细胞用于缺血性脑卒中的下一代再生治疗

  

  • 出版日期:2024-11-15 发布日期:2024-03-28

Next-generation regenerative therapy for ischemic stroke using peripheral blood mononuclear cells

Masato Kanazawa*, Itaru Ninomiya, Yutaka Otsu, Masahiro Hatakeyama   

  1. Department of Neurology, Brain Research Institute, Niigata University, Niigata, Japan
  • Online:2024-11-15 Published:2024-03-28
  • Contact: Masato Kanazawa, MD, PhD, masa2@bri.niigata-u.ac.jp.
  • Supported by:
    This work was supported by the JSPS KAKENHI Grant-in-Aid for Scientific Research (Grant number: 21K19441, 22H03183) (to MK), and Early-Career Scientists (Grant number: 21K15185) (to IN) and (Grant number: 20K16485) (to MH).

摘要: https://orcid.org/0000-0001-6337-8156 (Masato Kanazawa)

Abstract: Stroke is the second leading cause of death and the third leading cause of disability worldwide after heart disease. Researchers predict that stroke deaths and permanent disabilities will increase worldwide by the year 2050. Single-target therapies may be insufficient, because ischemic cerebral injury involves several mechanisms. Cell-mediated therapies are ideal, because they target multiple cell types to enhance protection and recovery. Sources for cell therapy include bone marrow-derived mesenchymal and embryonic stem cells. Although clinical trials on the administration of autologous mesenchymal stem cells have shown improved functional outcomes after ischemic stroke, the number of these cells is limited. Therefore, it requires time to obtain sufficient functionally mature cells for treatment. Simple and abundant cell sources, such as peripheral blood cells, are suitable for clinical applications.